Titan Biotech Limited

BSE: 524717
Titan Biotech Limited - life sciences in Bhiwadi, Rajasthan, India. FY 2026 financials & compliance.
CIN L74999RJ1992PLC013387 Incorporated 18 February 1992 ROC Jaipur HQ Bhiwadi, Rajasthan, India
Active Listed - BSE: 524717 Public Limited Company life sciences
Data last updated
Market Cap
₹1,818 Cr
TITANBIO · BSE
Share Price
₹361.80
+2.78% today
Revenue
₹206 Cr
FY 2025-26 · +31.8% YoY
EBITDA
₹38.60 Cr
Margin 18.7%
Net Profit
₹29.88 Cr
FY 2025-26 · +38.7% YoY
P/E (TTM)
47.9x
P/B 8.9x
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹8.26 Cr
Issued & subscribed

About Titan Biotech Limited

Data last updated:

Titan Biotech Limited is a public limited company based in Bhiwadi, Rajasthan, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 18 February 1992 and has been in existence for over 34 years.

The company is registered with the Registrar of Companies (ROC), Jaipur, under CIN L74999RJ1992PLC013387. Its GSTIN is 08AAACT0078J1ZA (Rajasthan). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 524717.

The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹8.26 Cr. It was formerly known as Titan Medicares Limited. It is led by directors including Naresh Singla (Managing Director) and Suresh Chand Singla (Managing Director).

Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at A – 902 A RIICO.Indl.Area Phase – III, Bhiwadi, Rajasthan, India – 301019.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹206.19 Cr, a growth of 31.8% compared to the previous year. For the same year it recorded a net profit of ₹29.88 Cr (net margin 14.5%) and EBITDA of ₹38.6 Cr (EBITDA margin 18.7%). The net worth stands at ₹181.54 Cr (up 18.3% YoY). Total assets are valued at ₹189.53 Cr (up 20.1% YoY).

The company has about 377 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Titan Biotech. As per MCA filings, the company has open charges of ₹21.19 Cr and satisfied charges of ₹37.52 Cr on record. Court records list 24 cases involving the company, including 16 filed by the company and 8 filed against it; 2 cases are pending.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website titanbiotechltd.com.

Company details

CIN L74999RJ1992PLC013387
Registration Number 013387
Incorporation Date 18 February 1992
ROC Jaipur
Listing Status Listed - Listed on BSE (524717)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Titan Biotech has undergone 2 name changes throughout its history. The company was previously known as Titan Medicares Limited, and Titan Biotech Limited. The current legal name is Titan Biotech Limited.

Company NameStatus
Titan Biotech LimitedCurrent
Titan Medicares LimitedPrevious

CIN history

Titan Biotech has one previous CIN (Corporate Identification Number): L74999RJ1997PLC013387. The current CIN is L74999RJ1992PLC013387, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74999RJ1992PLC013387Current
L74999RJ1997PLC013387Previous
Key People
Naresh Singla Managing Director Suresh Chand Singla Managing Director Raja Singla Whole-Time Director

Contact details

Titan Biotech Limited's registered office is in Bhiwadi, Rajasthan. Its website is titanbiotechltd.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    titanbiotechltd.com
  • Social Media
  • Registered Address
    A – 902 A RIICO.Indl.Area Phase – III, Bhiwadi, Rajasthan, India – 301019
  • Industry
    Life Sciences, Biotechnology

To see the full contact details of Titan Biotech Limited, buy the company report.

Comprehensive company report
Titan Biotech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Titan Biotech operates one associated brand: Titan Biotech. Each brand links to its own profile.

BrandDescriptionWebsite
Titan Biotech
Biological products are manufactured and exported for various industries.titanbiotechltd.com

Business activity

The main business activity of Titan Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Titan Biotech Limited, buy the company report.

Financials of Titan Biotech Limited

FY 2025-26 filings available

Titan Biotech Limited reported revenue of ₹206.19 Cr (up 31.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹206 Cr
+31.8% YoY
EBITDA
₹38.60 Cr
+51.8% YoY
Profit After Tax
₹29.88 Cr
+38.7% YoY
Net Worth
₹182 Cr
+18.3% YoY
Total Assets
₹190 Cr
+20.1% YoY
Total Debt
₹5.71 Cr
+104.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20615616414412414279.44
Revenue growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
EBITDA38.6025.4334.2829.5231.2745.8613.50
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+32.2%+17.0%
Profit before tax38.1724.3731.5328.1128.9742.7010.41
Net profit29.8821.5424.8524.8421.6930.576.61
Net profit margin+14.5%+13.8%+15.2%+17.3%+17.6%+21.5%+8.3%
EPS (₹)7.2326.0630.0730.0626.2436.718.55
Balance sheet
Total assets19015814312096.6189.7866.70
Net worth18215313311086.2468.7539.19
Total debt5.712.798.308.518.9315.9923.88
Cash & bank1.875.563.294.866.815.451.86
Net working capital63.2264.1660.2155.0453.5449.2736.10
Cash flow
Cash from operations30.4220.1221.1521.1822.0419.086.12
Cash from investing(32.55)(9.85)(20.30)(20.73)(16.44)(4.86)(2.21)
Cash from financing(1.53)(7.98)(2.87)(2.40)(4.10)(10.60)(3.95)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue59.1748.8356.5154.3546.5035.1738.2839.89
Revenue growth (YoY)+27.3%+38.8%+47.6%+36.3%+7.9%---
Other income1.812.111.261.320.721.381.590.32
EBITDA12.499.7110.839.328.744.574.857.76
EBITDA margin+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%+19.5%
Depreciation1.371.301.271.211.150.841.181.10
Interest0.200.240.260.220.200.080.150.27
Profit before tax12.7310.2810.569.218.115.035.116.71
Tax3.283.722.702.361.951.271.311.71
Net profit9.456.567.866.856.163.763.805.00
EPS (₹)2.631.6310.329.408.304.905.318.10
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20615616414412412269.48
Revenue growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
EBITDA38.6025.4334.2829.5231.2741.4510.87
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+33.9%+15.6%
Profit before tax38.1724.3731.5328.1128.9738.778.23
Net profit27.4418.2823.6621.0221.6929.025.73
Net profit margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.7%+8.3%
EPS (₹)6.6422.1128.6425.4426.2434.827.50
Balance sheet
Total assets17915013811696.6177.3256.92
Net worth17114512810686.2465.8237.81
Total debt5.712.798.308.518.9310.2617.86
Cash & bank1.875.562.844.866.815.311.73
Net working capital63.2264.1660.2055.0453.5442.1431.03
Cash flow
Cash from operations30.4220.1221.1521.1822.0417.596.92
Cash from investing(32.55)(9.85)(20.30)(20.73)(16.44)(4.17)(0.94)
Cash from financing(1.53)(7.98)(2.87)(2.40)(4.10)(9.81)(5.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue59.1748.8356.5154.3546.5035.1738.2839.89
Revenue growth (YoY)+27.3%+38.8%+47.6%+36.3%+7.9%---
Other income1.812.111.261.320.721.381.590.32
Total expenses46.6839.1245.6845.0337.7630.6033.4332.13
EBITDA12.499.7110.839.328.744.574.857.76
EBITDA margin+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%+19.5%
Depreciation1.371.301.271.211.150.841.181.10
Interest0.200.240.260.220.200.080.150.27
Profit before tax12.7310.2810.569.218.115.035.116.71
Tax3.283.722.702.361.951.271.311.71

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue59.1748.8356.5154.3546.5035.1738.2839.89
Revenue growth (YoY)+27.3%+38.8%+47.6%+36.3%+7.9%---
Other income1.812.111.261.320.721.381.590.32
EBITDA12.499.7110.839.328.744.574.857.76
EBITDA margin+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%+19.5%
Depreciation1.371.301.271.211.150.841.181.10
Interest0.200.240.260.220.200.080.150.27
Profit before tax12.7310.2810.569.218.115.035.116.71
Tax3.283.722.702.361.951.271.311.71
Net profit9.456.567.866.856.163.763.805.00
EPS (₹)2.631.6310.329.408.304.905.318.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20615616414412414279.44
Revenue growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
Other income5.413.911.751.940.940.791.06
Total expenses16813113011492.2896.3865.94
Employee cost0.0026.3823.7118.2114.2413.0911.51
EBITDA38.6025.4334.2829.5231.2745.8613.50
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+32.2%+17.0%
Depreciation4.934.173.332.602.372.221.80
Interest0.910.801.170.750.871.732.35
Profit before tax38.1724.3731.5328.1128.9742.7010.41
Tax10.736.097.877.097.2811.002.57
Net profit29.8821.5424.8524.8421.6930.576.61
Net profit margin+14.5%+13.8%+15.2%+17.3%+17.6%+21.5%+8.3%
EPS (₹)7.2326.0630.0730.0626.2436.718.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.268.268.268.268.268.268.26
Reserves & surplus17314512510277.9860.4930.93
Shareholders' funds (net worth)18215313311086.2468.7539.19
Minority interest0.000.000.000.000.003.722.35
Secured loans3.672.106.757.009.2611.7213.94
Unsecured loans2.040.691.551.51(0.33)4.279.94
Total debt5.712.798.308.518.9315.9923.88
Total liabilities19015814312096.6189.7866.70
Assets
Gross block88.1580.7571.3352.4648.9745.5140.85
Net block61.6157.2752.0135.8934.9933.6131.16
Capital work in progress1.731.702.5513.293.630.270.07
Investments60.3632.7728.1915.414.030.000.00
Inventories55.7750.8245.5736.1734.6832.5427.98
Sundry debtors22.8318.8218.6621.0116.3618.1011.86
Cash & bank balances1.875.563.294.866.815.451.86
Loans & advances4.774.315.116.275.902.742.51
Total current assets85.2479.5172.6368.3163.7558.8344.21
Total current liabilities22.0215.3512.4213.2710.219.568.11
Net working capital63.2264.1660.2155.0453.5449.2736.10
Total assets19015814312096.6189.7866.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5.132.844.866.815.311.831.87
Net cash from operating activities30.4220.1221.1521.1822.0419.086.12
Net cash from investing activities(32.55)(9.85)(20.30)(20.73)(16.44)(4.86)(2.21)
Net cash from financing activities(1.53)(7.98)(2.87)(2.40)(4.10)(10.60)(3.95)
Net change in cash(3.65)2.29(2.02)(1.95)1.513.62(0.04)
Closing cash1.875.563.294.866.815.451.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
EBITDA growth+51.8%-25.8%+16.1%-5.6%-31.8%+239.7%-
PBT growth+56.6%-22.7%+12.2%-3.0%-32.2%+310.2%+87.9%
Net income growth+38.7%-13.3%+0.0%+14.5%-29.1%+362.5%-
Revenue CAGR (3Y)+12.7%+8.2%+4.9%+21.9%+23.9%+35.4%+14.6%
EBITDA CAGR (3Y)+9.4%-6.7%-9.3%+29.8%+52.0%+87.3%+36.0%
Profitability & leverage
Net income margin+13.3%+11.7%+14.4%+14.6%+17.6%+22.3%+9.9%
Return on capital employed-+16.7%+24.8%+26.6%+32.7%+59.1%+21.1%
Return on net worth-+12.7%+19.4%+21.4%+28.0%+58.8%+22.0%
Debt / equity-0.040.070.090.160.370.67
Long-term debt / equity-0.010.010.020.060.160.35
Interest cover2.703.763.782.793.013.9620.09
Efficiency & per share
Fixed asset turnover-2.062.652.842.623.292.04
Inventory turnover-3.254.014.063.684.703.24
Debtors turnover-8.358.277.717.179.507.53
EPS (₹)7.2326.0630.0730.0626.2436.718.55
Dividend per share (₹)0.502.002.001.801.501.501.00
Book value per share (₹)0.00185.64161.49133.00104.3683.2147.43
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue59.1748.8356.5154.3546.5035.1738.2839.89
Revenue growth (YoY)+27.3%+38.8%+47.6%+36.3%+7.9%---
Other income1.812.111.261.320.721.381.590.32
Total expenses46.6839.1245.6845.0337.7630.6033.4332.13
EBITDA12.499.7110.839.328.744.574.857.76
EBITDA margin+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%+19.5%
Depreciation1.371.301.271.211.150.841.181.10
Interest0.200.240.260.220.200.080.150.27
Profit before tax12.7310.2810.569.218.115.035.116.71
Tax3.283.722.702.361.951.271.311.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20615616414412412269.48
Revenue growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
Other income5.413.911.751.940.940.751.02
Total expenses16813113011492.2881.0158.61
Employee cost0.0026.3823.7118.2114.2411.089.07
EBITDA38.6025.4334.2829.5231.2741.4510.87
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+33.9%+15.6%
Depreciation4.934.173.332.602.372.101.75
Interest0.910.801.170.750.871.331.91
Profit before tax38.1724.3731.5328.1128.9738.778.23
Tax10.736.097.877.097.289.992.04
Net profit27.4418.2823.6621.0221.6929.025.73
Net profit margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.7%+8.3%
EPS (₹)6.6422.1128.6425.4426.2434.827.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.268.268.268.268.268.268.26
Reserves & surplus16313712097.8377.9857.5629.55
Shareholders' funds (net worth)17114512810686.2465.8237.81
Secured loans3.672.107.177.009.268.6111.00
Unsecured loans2.040.691.131.51(0.33)1.656.86
Total debt5.712.798.308.518.9310.2617.86
Total liabilities17915013811696.6177.3256.92
Assets
Gross block88.1580.7571.3352.4648.9738.6934.79
Net block61.6157.2752.0135.8934.9927.0425.24
Capital work in progress1.731.702.5513.293.630.270.00
Investments49.6624.5023.1811.594.031.271.27
Inventories55.7750.8245.5736.1734.6826.8324.14
Sundry debtors22.8318.8218.6621.0116.3616.1210.54
Cash & bank balances1.875.562.844.866.815.311.73
Loans & advances4.774.315.116.275.901.381.70
Total current assets85.2479.5172.1868.3163.7549.6438.11
Total current liabilities22.0215.3511.9813.2710.217.507.08
Net working capital63.2264.1660.2055.0453.5442.1431.03
Total assets17915013811696.6177.3256.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5.132.844.866.815.311.701.59
Net cash from operating activities30.4220.1221.1521.1822.0417.596.92
Net cash from investing activities(32.55)(9.85)(20.30)(20.73)(16.44)(4.17)(0.94)
Net cash from financing activities(1.53)(7.98)(2.87)(2.40)(4.10)(9.81)(5.87)
Net change in cash(3.65)2.29(2.02)(1.95)1.513.610.11
Closing cash1.875.562.844.866.815.311.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
EBITDA growth+51.8%-25.8%+16.1%-5.6%-24.6%+281.3%-
PBT growth+56.6%-22.7%+12.2%-3.0%-25.3%+371.1%+89.2%
Net income growth+50.1%-22.7%+12.6%-3.1%-25.3%+406.5%-
Revenue CAGR (3Y)+12.7%+8.2%+10.2%+27.5%+28.5%+30.2%+9.8%
EBITDA CAGR (3Y)+9.4%-6.7%-6.1%+39.5%+61.2%+84.7%+25.3%
Profitability & leverage
Net income margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.5%+8.9%
Return on capital employed-+17.5%+25.7%+27.1%+34.3%+59.7%+18.3%
Return on net worth-+13.4%+20.2%+21.9%+28.5%+55.5%+17.9%
Debt / equity-0.040.070.090.130.270.57
Long-term debt / equity-0.010.010.020.040.110.30
Interest cover2.703.763.782.793.013.3820.94
Efficiency & per share
Fixed asset turnover-2.062.652.842.823.332.03
Inventory turnover-3.254.014.064.024.813.15
Debtors turnover-8.358.277.717.619.197.56
EPS (₹)6.6422.1128.6425.4426.2434.827.50
Dividend per share (₹)0.502.002.001.801.501.501.00
Book value per share (₹)0.00175.63155.43128.38104.3679.6545.76

To see the full year-wise statements and ratios of Titan Biotech Limited, buy the company report.

Board of directors of Titan Biotech Limited

Titan Biotech has 12 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Manju Singla
Also directs: Titan Securities Limited, Peptech Biosciences Limited, Tanita Leasing & Finance Limited and 1 more
Director23 Jun 200125 Years 4 MonthsCurrent
Supriya Singla
Also directs: Peptech Biosciences Limited, Titan Agritech Limited, Suptex Industries Private Limited and 4 more
Director01 Oct 201214 Years 0 MonthsCurrent
Raja Singla
Also directs: Titan Agritech Limited, Satvik Realtech LLP, Snap House LLP and 5 more
Whole-Time Director01 Oct 20224 Years 0 MonthsCurrent
Naresh Singla
Also directs: Titan Securities Limited, Titan Media Limited, Peptech Biosciences Limited and 4 more
Managing Director01 May 200224 Years 5 MonthsCurrent
Suresh Chand Singla
Also directs: Titan Securities Limited, Titan Media Limited, Peptech Biosciences Limited and 5 more
Managing Director01 Oct 201214 Years 0 MonthsCurrent
Rohit Jain
Also directs: Peptech Biosciences Limited, Singhania &Co- LLP, S&Co. (Ifsc) LLP and 5 more
Director26 Jul 20215 Years 3 MonthsCurrent
Showing 6 of 12 current directors. View all directors

Auditor

Titan Biotech Limited is audited by A N S K & ASSOCIATES for the financial year 2023.

Auditor firmFinancial yearFirm registration number
A N S K & ASSOCIATESFY 2023026177N

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 55.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 44.20%.

Promoters: 55.80%Retail & Others: 44.20%
Mar 2026
QUARTER
55.80% Promoters
44.20% Retail & Others
Promoter holding - history
Now 55.80% · Mar 2026High 55.90% · Jun 2025Low 55.80% · Sep 2025
54%54.8%55.5%56.3%57%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 55.90%Sep 2025: 55.80%Dec 2025: 55.80%Mar 2026: 55.80%55.90%55.80%55.80%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters55.80%55.80%55.80%55.90%
Public44.20%44.20%44.20%44.10%

Charges & borrowings

Open charges
₹21.19 Cr
Satisfied charges
₹37.52 Cr
Breakdown by lending institutions
Others₹17.00 Cr
Hdfc Bank Limited₹4.19 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Oct 2025101200775Hdfc Bank Limited₹45 LakhOpen
30 Dec 2024101027884Others₹17 CrOpen
13 Dec 2024101038017Hdfc Bank Limited₹3.02 CrOpen
12 Aug 2024100962419Hdfc Bank Limited₹12 LakhOpen
21 Jul 2022100633826Hdfc Bank Limited₹45 LakhOpen

To see the full charge records of Titan Biotech Limited, buy the company report.

Total charge records: 10 View all charges

MSME payment delays

Titan Biotech Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 16 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 8)

SupplierAmount dueDue sinceReported on
an individual supplier
Oxford Lab Fine Chem LLP
an individual supplier
DRWS Private Limited
an individual supplier

To see the full MSME payment records of Titan Biotech Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Titan Biotech has 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Associated companies

Employees & EPFO

Titan Biotech Limited has a workforce of 377 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.

Employee count
377
Active EPFO establishments
1
Employee growth
30.9%

GST

Titan Biotech has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
08AAACT0078J1ZARajasthanActive01 Jul 2017
07AAACT0078J1ZCDelhiActive01 Jul 2017

To see the full GST registrations and return filing status of Titan Biotech Limited, buy the company report.

Recent activity

Titan Biotech Limited has 30 board changes on record since 1997: 22 appointments and 8 cessations. The latest: Debendra Kumar Sabat was appointed as Director on 13 Aug 2025.

Filing
Titan Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Jaipur.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.45 Cr with Charge ID 101200775 was registered on 30 Oct 2025.
AGM
Titan Biotech Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Appointed
Debendra Kumar Sabat was appointed as Director.
Charges
A charge with Hdfc Bank Limited of Rs. 3.02 Cr registered on 13 Dec 2024 with Charge ID 101038017 was modified on 22 Jul 2025.
Charges
A charge registered on 08 Sep 2022 via Charge ID 100646281 with Hdfc Bank Limited was fully satisfied on 14 Jan 2025.
Charges
A charge registered on 22 Aug 2015 via Charge ID 10594682 with Hdfc Bank Limited was fully satisfied on 14 Jan 2025.
Charges
A charge with Others amounted to Rs. 17.00 Cr with Charge ID 101027884 was registered on 30 Dec 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 3.02 Cr with Charge ID 101038017 was registered on 13 Dec 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.12 Cr with Charge ID 100962419 was registered on 12 Aug 2024.
Appointed
Brijesh Kumar Singh was appointed as Director.
Appointed
Dhairya Madan was appointed as Director.

39 earlier events are in the company report.

News

Frequently asked questions

Titan Biotech is an active public limited company based in Bhiwadi, Rajasthan, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 18 February 1992 (34+ years old) and is registered under CIN L74999RJ1992PLC013387. Listed on BSE: 524717.

Titan Biotech reported revenue of ₹206.19 Cr for FY 2025-26 (up 31.8% YoY) based on consolidated financials.

Titan Biotech has 12 current directors:

The latest financial statements of Titan Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Titan Biotech is 08AAACT0078J1ZA, registered in Rajasthan. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 07AAACT0078J1ZC (Delhi).

The CIN (Corporate Identification Number) of Titan Biotech is L74999RJ1992PLC013387. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Titan Biotech is a listed company as per MCA records. Its shares are listed on BSE (code: 524717).

Titan Biotech has 24 court cases on record: 16 filed by the company and 8 filed against it. 2 are pending. Most are in the district courts.

Titan Biotech was incorporated on 18 February 1992, making it 34+ years old. It is registered with the Registrar of Companies, Jaipur.

Debendra Kumar Sabat was appointed as Director on 13 Aug 2025. Brijesh Kumar Singh was appointed as Director on 01 Oct 2023. Dhairya Madan was appointed as Director on 01 Oct 2023. Titan Biotech has 30 board changes on record in total.

Titan Biotech has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 16 overdue payments to 8 micro and small suppliers. The latest return was filed on 30 Apr 2024.